Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease – DocWire News

This article was originally published here

Vaccines (Basel). 2022 Apr 20;10(5):646. doi: 10.3390/vaccines10050646.

ABSTRACT

BACKGROUND: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease.

METHODS: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA).

RESULTS: The cost per responder for ACR 20 was 19,846 versus 19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were 27,820 versus 27,384 and 22,102 versus 32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was 34,072 and 38,906 for secukinumab versus adalimumab.

CONCLUSIONS: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab.

PMID:35632402 | DOI:10.3390/vaccines10050646

Read more here:
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease - DocWire News